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CTLA-4 Blockade Reverses CD81 T Cell
Tolerance to Tumor by a CD41 T Cell±
and IL-2-Dependent Mechanism
CD81 T cells following activation (Walunas et al., 1994)
and has been implicated in the induction and mainte-
nance of tolerance in vivo (Chambers et al., 1996; Perez
et al., 1997). Therapeutic effects were obtained when
anti-CTLA-4 mAb was administered to tumor-bearing
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The precise nature of the role of CD41 T cells in gener-
ating tumor-specific CD81 T cell responses remains un-
clear. E.G7 tumor cells, EL-4 thymoma transfected withSummary
the OVA gene (Moore et al., 1988), have been used in
several studies of immunotherapy (Newman et al., 1992;A tumor-specific CD81 T cell response was studied
using adoptive transfer of OT-I TCR transgenic cells. Zhou et al., 1992; Fenton et al., 1993; Minev et al., 1994;
Porgador et al., 1996; Brossart et al., 1997) and provideUpon i.p. challenge with E.G7 tumor, OT-I cells un-
dergo CD41 T cell±independent expansion at the tumor a good model for studying CD41 and CD81 T cell collab-
oration since the pseudo-tumor antigen OVA includessite and develop lytic function. Before tumor elimina-
tion, however, they leave the peritoneal cavity (PC) epitopes recognized by both subsets. We have pre-
viously employed adoptive transfer of TCR transgenicand appear in the LN and spleen where they exhibit
ªsplit anergyº and cannot further proliferate to antigen. OT-I T cells, specific for OVA257-264 peptide bound to
H-2Kb (Hogquist et al., 1994), to study the CD81 T cellAdministering anti-CTLA-4 mAb early caused sustained
OT-1 expansion in the PC, and late administration response to E.G7 (Shrikant and Mescher, 1999). The OT-I
cells clonally expanded at the site of tumor, developedcaused the OT-I cells to return to the PC and further
expand; in both cases, tumor was controlled. These effector function, and transiently controlled tumor
growth. However, within a few days expansion stopped,effects required CD41 T cells and IL-2 and appear to
result from reversal of the nonresponsive state of the the effector cells migrated away from the tumor site,
and tumor progressed. OT-I cells remained present inCD81 T cells.
the spleen and draining lymph nodes (LN) but were non-
responsive when examined in vitro. This resembles theIntroduction
situation in some human cancers where tumor-specific
T cells with a memory phenotype can be found in theIdentification of tumor antigens recognized by both
circulation but tumor is not being controlled (D'SouzaCD41 and CD81 T cells has generated renewed enthusi-
et al., 1998; Jantzer and Schendel, 1998; Lee et al., 1999).asm for the potential of effective cancer immunotherapy
We have now examined the effects of CTLA-4 blockade(Boon et al., 1994; Topalian et al., 1996; Halder et al.,
and the contribution of host OVA-specific CD41 T cells1997; Chaux et al., 1999; Manici et al., 1999; Pieper et
and IL-2 to the OT-I response. The results demonstrateal., 1999). CD81 T cells specific for tumor antigens can
that tolerance of the CD81 T cells can be prevented oroften be demonstrated in tumor-bearing hosts, and ef-
reversed via a CD41 T cell, IL-2-dependent mechanismfector cytotoxic T lymphocytes (CTL) have been histori-
upon administration of anti-CTLA-4 mAb. IL-2 appearscally thought to be the major component of an immune
to be necessary and sufficient to mediate the help pro-response to most tumors. The importance of CD41 T cell
vided by the CD41 T cells, and administration of low-help for many CD81 T cell responses is well established.
dose IL-2 alone can reverse tolerance. These resultsThis may involve ªconditioningº APC to more effectively
have implications for the potential to reactivate tumor-present antigen to CD81 T cells (Bennett et al., 1998;
specific CTL for tumor immunotherapy.Ridge et al., 1998; Schoenberger et al., 1998) or produc-
tion of IL-2 or other cytokines to support the CD81 T
cell response. CD81 T cell responses to viral infections Results
are of short duration in the absence of CD41 T cells,
and help is usually required for a sustained, effective Blocking CTLA-4 Interactions Enhances
and Prolongs a Tumor-Specificresponse (Matloubian et al., 1994; Cardin et al., 1996;
Stevenson et al., 1998; Zajac et al., 1999). CD41 T cells CD81 T Cell Response
Transfer of 4 3 106 LN cells from OT-I mice into Thy 1can also be necessary for supporting tumor-specific
CD81 T cell responses (Greenberg et al., 1981; Keene congenic C57BL/PL recipients by i.v. injection results
in rapid equilibration into the lymphoid organs; withinand Forman, 1982; Ossendorp et al., 1998; Pardoll and
Topalian, 1998), and early induction of tolerance in tu- 24 hr, 0.1 to 0.3% of the lymphocytes in the LN or spleen
are Thy 1.21CD81 OT-I T cells (Shrikant and Mescher,mor-specific CD41 T cells may limit the immune re-
sponse that can occur to the tumor (Staveley-O'Carroll 1999). When these mice are then challenged intraperito-
neally (i.p.) with E.G7 tumor, an OVA-expressing trans-et al., 1998). CTLA-4 is expressed by both CD41 and
fected line of the EL-4 thymoma, the OT-I cells undergo
clonal expansion preferentially in the peritoneal cavity³To whom correspondence should be addressed (e-mail: mesch
001@maroon.tc.umn.edu). (PC), the site of tumor growth, by day 4 (Figures 1Aa
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Figure 1. CTLA-4 Blockade Results in a Sus-
tained CD41 T Cell±Dependent Response of
OT-I CD81 T Cells to Syngeneic Tumor
(A) OT-I CD81Thy 1.21 T cells were trans-
ferred into Thy 1 congenic recipients and the
mice challenged i.p. 1 day later (day 0) with
E.G7 (ªtransfer 1 tumorº). Some mice re-
ceived OT-I cells but were not challenged
with tumor (ªtransfer onlyº). Some groups
that received OT-I and E.G7 were also treated
with either isotype control antibody (250 mg/
day) at days 2, 4, and 6 (ªisotype controlº),
anti-CTLA-4 mAb (250 mg/day) at days 2, 4,
and 6 (ªanti-CTLA-4 d2, 4, 6º), anti-CD4 mAb
on days 21, 0, and 1 to deplete CD41 T cells
(ªanti-CD4-1, 0, 1º), or both anti-CD4 mAb
and anti-CTLA-4 mAb (ªanti-bothº). OT-I
numbers were determined in LN and PC on
days 4 and 10. ND, not determined. Groups
had two mice each; values shown are aver-
ages, and error bars indicate the range. The
experiment shown is representative of three
independent experiments. (B) Tumor cells
were recovered from the peritoneal cavities
of mice in (A) and quantitated. (C) Detection
of OT-I cells from the PC of antibody-treated
mice. At day 10 post tumor challenge, OT-I
cells from mice described above (A) were de-
tected by staining with anti-Thy 1.2 and anti-
CD8 mAbs. Boxed regions indicate the events
identified as OT-I cells (top panels). For mice
that received anti-CTLA-4 mAb, OT-I cells
(CD81/Thy 1.21) were compared to total host
CD81 T cells (CD81) for forward scatter and
CD25 expression (bottom panels).
and 1Ac). By day 10, however, the OT-I cells have disap- on both CD41 and CD81 T cells (Leach et al., 1996;
Kwon et al., 1997; Yang et al., 1997; Hurwitz et al., 1998).peared from the PC (Figure 1Ag), and increased num-
bers are now present in the LN (Figure 1Ae) and spleen Experiments were therefore done to determine if CTLA-4
might be playing a role in the decline of the OT-I re-(data not shown), despite continued growth in the PC
(Figures 1Bc) of tumor that still expresses antigen (Shri- sponse. When anti-CTLA-4 mAb was administered on
days 2, 4, and 6 after challenge with E.G7, increasedkant and Mescher, 1999). We found that the OT-I cells
in the LN and spleen at this time still have active lytic numbers of OT-I cells were present in the LN by day 10,
in comparison to mice treated with an isotype controleffector function but are anergic in that they cannot
respond to antigen in vitro unless exogenous IL-2 is antibody (Figure 1Af). More dramatically, the anti-
CTLA-4 mAb-treated mice still had high numbers of OT-Iprovided (Shrikant and Mescher, 1999). Thus, the anti-
gen-specific CD81 T cells make an initial response at cells in the PC at day 10 (Figure 1Ah), and tumor cell
numbers were much lower (Figure 1Bd). Administrationthe site of tumor growth but migrate away from the site
and become nonresponsive before the tumor is elimi- of anti-CTLA-4 mAb to mice that had not received OT-I
cells by adoptive transfer did not cause a decrease innated.
CTLA-4 expression is upregulated on activated T cells tumor load on day 10. In a representative experiment,
mice that had received OT-I by adoptive transfer andand is responsible for induction of tolerance of CD41 T
cells in some systems (Walunas et al., 1994; Chambers were treated with isotype control antibody had 11.8 6
2.6 3 106 E.G7 on day 10, while mice treated with anti-et al., 1996; Perez et al., 1997). Furthermore, blocking
CTLA-4 function in vivo with anti-CTLA-4 mAb can en- CTLA4 mAb had 2.1 6 0.5 3 106 E.G7. In contrast, mice
that did not receive OT-I cells but were treated with anti-hance tumor-specific immune responses that depend
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Figure 3. CD41 T Cells from Anti-CTLA-4 mAb-Treated Animals Re-
spond to Antigenic Restimulation In VitroFigure 2. In Vivo Blockade of CTLA-4 Interactions in CD42/2 Recipi-
ent Mice Results in No Augmentation of OT-I Response Mice received OT-I cells on day 21, E.G7 on day 0, and either
hamster IgG control antibody (250 mg/day) or anti-CTLA-4 mAb (250(A) OT-I/PL cells (CD81/Thy 1.11) at day 10 post E.G7 challenge
mg/day) on days 2, 4, and 6. CD41 T cells were isolated from spleenswere enumerated from the PC, spleen (Spl), and the draining LN of
and LN at day 10 post tumor challenge, purified, and stimulated inC57Bl/6 CD42/2 mice that had been treated at days 2, 4, and 6 with
vitro with antigen for 3 days.either hamster IgG at 250 mg/day (isotype control d2, 4, and 6) or
(A) CD41 T cells (1 3 105) were stimulated with the indicated concen-anti-CTLA-4 antibody at 250 mg/day (anti-CTLA-4 d2, 4, and 6). The
trations of OVA in the presence of 1 3 106 spleen cells, and prolifera-experiment shown is representative of two independent experi-
tion was determined on day 3. Results are shown as averages andments. (B) Number of E.G7 cells in the PC of mice at day 10 post
SD of triplicate samples. The experiment shown is representativetumor challenge. Mice were those examined in (A) treated as indi-
of two independent experiments.cated.
(B) Cells were stimulated as in (A) but using 5 3 105 responder
cells, and the IL-2 content of the culture supernatant at day 3 was
determined by ELISA. Values shown are averages SD of triplicate
CTLA4 mAb had 12.4 6 1.5 3 106 E.G7. Thus, OT-I are samples. The experiment shown is representative of two indepen-
the effector cells mediating the tumor reduction in these dent experiments.
experiments. Most OT-I cells in the PC of anti-CTLA-4
mAb-treated mice at day 10 had an activated phenotype,
with high forward scatter (blast transformation) and IL- up in the LN (Figure 1Af), just as in normal recipients.
2R (CD25) expression (Figure 1C). The OT-I cells in the However, CD41 T cell depletion completely eliminated
LN at day 10 had a similar phenotype (data not shown). the enhancement and prolongation of OT-I responses
In contrast, OT-I cells that have migrated to the LN (Figures 1Af and 1Ah) and reduction of tumor load (Fig-
of untreated tumor-bearing mice by day 10 have low ure 1Bd) caused by anti-CTLA-4 mAb. Thus, OT-I T cells
forward scatter and are IL-2R2 (Shrikant and Mescher, make a transient T helper±independent response to the
1999). Thus, blocking CTLA-4 interactions caused an tumor, and this response can be expanded and pro-
increased and prolonged expansion of antigen-specific longed by CD41 T cells, but only if CTLA-4 interactions
CD81 T cells at the site of tumor growth. are blocked.
These conclusions were confirmed by examining OT-I
responses after adoptive transfer into CD42/2 mice thatCD41 T Cells Are Required for Anti-CTLA-4
mAb-Mediated Enhancement of the CD81 lack CD41 T cells. The CD42/2 mice are on the C57BL/6
background, so CD81 cells from OT-I 3 C57BL/PL F1T Cell Response
To determine if CD41 T cells were involved in the OT-I mice were used as recipients, with OT-I cells being de-
tected by staining with anti-Thy 1.1 and anti-CD8 mAbs.response and in the enhancement caused by anti-
CTLA-4 mAb, mice were depleted of CD41 T cells prior By day 10, the OT-I cells had disappeared from the PC
and were increased in the spleen and LN (Figure 2A),to adoptive transfer and challenge (, 0.5% CD41 T cells
at day 10 after tumor challenge). Depletion had no effect and treating with anti-CTLA-4 mAb did not significantly
affect the numbers of either OT-I cells (Figure 2A) oron the response of OT-I cells to tumor. The number of
OT-I cells was increased at day 4 in the PC (Figure 1Ad) tumor cells (Figure 2B). Thus, the OT-I response in
CD42/2 mice is essentially identical to the response inand by day 10 was down in the PC (Figure 1Ah) and
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Figure 4. IL-2 Is Required for the OT-I Re-
sponse in the Absence or Presence of Anti-
CTLA-4 mAb
(A) OT-I recipients were challenged with E.G7
on day 0 and treated with either rat IgG con-
trol antibody (1 mg/day) or rat anti-mouse IL-2
mAb (1 mg/day) at days 0 and 2 post tumor
challenge. Numbers of OT-I cells (CD81/Thy
1.21) in the spleen (Spl) and the PC and num-
bers of E.G7 cells (CD82/Thy 1.21) in the PC
were determined at day 4 post tumor chal-
lenge. The experiment shown is representa-
tive of three independent experiments.
(B) OT-I were challenged with E.G7 on day 0
and treated with hamster IgG control anti-
body (250 mg/day) or anti-CTLA-4 mAb (250
mg/day) on days 2, 4, and 6 post tumor chal-
lenge. Groups also received either rat IgG
control antibody (1 mg/day) or rat anti-mouse
IL-2 mAb (1 mg/day) on days 4, 5, and 6 post
tumor challenge. Numbers of OT-I cells
(CD81/Thy 1.21) in the spleen (Spl) and the PC
and numbers of E.G7 cells (CD82/Thy 1.21) in
the PC were determined at day 10 post tumor
challenge. The experiment shown is repre-
sentative of three independent experiments.
normal mice (Figure 1A), but anti-CTLA-4 mAb has no OT-I response. Whether IL-2 is necessary for the initial,
CD41 T cell±independent OT-I response was first exam-effect in the absence of CD41 T cells.
ined, using anti-IL-2 mAb on days 0 and 2 to neutralize
IL-2 produced in vivo. OT-I recipients that received anAnti-CTLA-4 mAb Treatment Enhances
Antigen-Specific Responses of CD41 isotype control mAb showed the expected response on
day 4 with respect to the numbers and locations of OT-IT Cells from Tumor-Bearing Mice
These results suggested that anti-CTLA-4 mAb was af- T cells and tumor cells. Anti-IL-2 mAb treatment almost
completely eliminated the OT-I expansion that occursfecting the response at the level of the endogenous host
CD41 T cells. We examined this by assessing the in in the PC by day 4 (Figure 4Ab). Thus, the initial CD41
T cell±independent expansion of OT-I requires IL-2,vitro responsiveness of CD41 T cells isolated from the
antibody-treated mice. CD41 T cells from OT-I recipients probably produced by the antigen-specific CD81 T cells
themselves.challenged 10 days previously with tumor and treated
with isotype control antibody were almost completely Anti-IL-2 mAb treatment was also used to determine
if the sustained response resulting from anti-CTLA-4unresponsive to OVA stimulation in vitro, as assessed
by either proliferation (Figure 3A) or IL-2 secretion (Fig- treatment also requires IL-2. When recipients were
treated with anti-CTLA-4 mAb on days 2, 4, and 6, theure 3B). In contrast, CD41 T cells taken on day 10 from
anti-CTLA-4 mAb-treated mice on days 2, 4, and 6 prolif- expected increase in OT-I numbers in the spleen (Figure
4Ba) and PC (Figure 4Bb) were observed on day 10, anderated vigorously to OVA (Figure 3A) and produced IL-2
(Figure 3B). Thus, OVA responsive CD41 T cells are only tumor was substantially reduced (Figure 4Bc). Anti-IL-2
mAb on days 4, 5, and 6 eliminated these effects of anti-detected in anti-CTLA-4 mAb-treated mice, suggesting
that they either fail to expand in the tumor-bearing host CTLA-4 mAb treatment; the number of OT-I cells was
reduced to that of the isotype control mice (Figures 4Baor expand but become tolerized unless CTLA-4 interac-
tions are blocked. Since the specific CD41 T cells cannot and 4Bb), and tumor load remained high (Figure 4Bc).
Thus, IL-2 is necessary for both the early CD41 T helperbe visualized in these experiments, we cannot distin-
guish between these possibilities. cell±independent phase of the OT-I response (Figure 4A)
as well as for the enhanced and prolonged response
that occurs when CD41 T cell help is provided (Fig-IL-2 Is Necessary and Sufficient to Support
a Sustained Antigen-Specific CD81 T Cell ure 4B).
The above experiments demonstrated that IL-2 is nec-Response at the Site of Tumor Growth
OT-I cells make an initial T helper±independent re- essary for a sustained OT-I response. Whether IL-2 is
sufficient was examined by administering rIL-2 by i.p.sponse in vivo (Figure 1) but then become anergic and
only respond to OVA in vitro if exogenous IL-2 is pro- injection during the response. When rIL-2 was given on
days 2 and 3, there was little effect on OT-I (Figurevided (Shrikant and Mescher, 1999). This suggested that
the ability of CD41 T cells to support a sustained OT-I 5Aa) or tumor cell numbers (Figure 5Ab) on day 4. This
suggests that the endogenous IL-2 produced during theresponse upon anti-CTLA-4 mAb administration might
result from them providing IL-2 to the CD81 T cells. This early, T helper±independent phase of the response is
sufficient to fully support the expansion of the OT-I cells.would be consistent with the ability of CD41 T cells
from anti-CTLA-4 mAb-treated mice to produce IL-2 in In contrast, rIL-2 administration on days 4 and 5 caused
a dramatic increase in the number of OT-I cells in theresponse to antigen (Figure 3B). We therefore deter-
mined the role of IL-2 in enhancing and sustaining the PC on day 10 (Figure 5Ba) and a large reduction in tumor
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Figure 5. Administration of IL-2 Mimics the
Effect of Anti-CTLA-4 mAb on the OT-I Re-
sponse to Tumor
(A) Mice received OT-I cells on day 21 and
were challenged with E.G7 on day 0. On days
2 and 3, groups received i.p. either PBS or
2000 IU of rIL-2. Numbers of OT-I cells in the
spleen (Spl) and PC and tumor cells in the PC
were determined on day 4. The experiment
shown is representative of three independent
experiments.
(B) Mice received OT-I cells on day 21 and
were challenged with E.G7 on day 0. On days
4 and 5, groups received i.p. either PBS or
2000 IU of rIL-2. Numbers of OT-I cells in the
spleen (Spl) and PC and tumor cells in the PC
were determined on day 10. The experiment
shown is representative of three independent
experiments.
(C) Treatment was the same as (B) but using
as OT-I recipients mice that had been de-
pleted of CD41 T cells by treatment with anti-
CD4 mAb, as described in the Experimental
Procedures. Mice had , 1% CD41 T cells at
the time of analysis on day 10.
cell number (Figure 5Bb), similar to the effects seen with of late (day 10) administration of anti-CTLA-4 mAb in
mice that had been depleted of CD41 T cells by anti-anti-CTLA-4 mAb. Thus, IL-2 is sufficient to support a
sustained CD81 T cell response at the site of tumor CD4 mAb treatment. Depletion of CD41 T cells was con-
firmed to eliminate the day 10 increase in OT-I cells ingrowth. This appears likely to be a direct effect on the
CD81 T cells, since essentially identical effects are ob- the LN (Figure 6Aa) and the decrease in tumor (Figure
6Ba) that result from early anti-CTLA-4 mAb treatmenttained when the recipients of OT-I adoptive transfer are
depleted of CD41 T cells (Figure 5C). Thus, IL-2 is both on days 2, 4, and 6. Similarly, when anti-CTLA-4 mAb
was administered on days 12, 14, and 16, the numbersnecessary (Figure 4B) and sufficient (Figures 5B and 5C)
for the sustained response of antigen-specific CD81 T of OT-I cells in the LN (Figure 6Af) and PC (Figure 6Ah)
were significantly higher than controls on day 22. Thiscells at the site of tumor growth.
was particularly striking for the PC, where OT-I cells
could be detected only in the mice that had receivedBlocking CTLA-4 Interactions Reverses Tolerance
of CD81 T Cells anti-CTLA4 mAb and tumor was reduced (Figure 6Bd).
Depletion of CD41 T cells eliminated both the increaseIn the experiments described thus far, anti-CTLA-4 mAb
was given on days 2, 4, and 6 after tumor challenge, in OT-I numbers (Figures 6Af and 6Ah) and the decrease
in tumor (Figure 6Bd) at this time. The CD41 T cell depen-and the effects can be interpreted as the mAb preventing
the induction of tolerance of the OT-I T cells. Kwon et dence of the late effects of anti-CTLA-4 mAb were fur-
ther confirmed in experiments showing that when theal. (1997) showed that late administration of anti-CTLA-4
mAb to an animal with progressing tumor can also adoptive transfer recipients are CD42/2 mice, late ad-
ministration of the mAb has no effect on the OT-I re-enhance an antitumor immune response. We examined
this in the OT-I T cell and E.G7 tumor system to deter- sponse (data not shown). Thus, CTLA-4 blockade can
reverse the tolerance of CD81 T cells that have beenmine if CTLA-4 blockade might be able to not only pre-
vent the induction of tolerance but possibly also reverse rendered nonresponsive following an initial response to
the tumor, and this reversal is completely dependenttolerance after it is established. Initial experiments
showed that administration of anti-CTLA-4 mAb to nor- upon CD41 T cells.
mal C57BL/PL recipients of OT-I cells 10 days after
tumor challenge resulted in high numbers of OT-I cells Priming CD41 T Cells prior to Tumor Challenge
Results in Enhanced and Sustained CD81in the PC on day 22 and a substantial reduction in tumor
(data not shown). Since antigen-specific OT-I cells have T Cell Responses to the Tumor
The experiments described thus far demonstrate thatresponded and left the tumor site by day 10 (Figure
3) and are tolerant (Shrikant and Mescher, 1999), this CD41 T helper cells can respond to tumor antigen and
sustain the response of CD81 OT-I T cells but only whenindicated that CTLA-4 blockade was reversing tol-
erance. CTLA-4 interactions of the CD41 T cells are blocked.
These results predicted that tumor antigen-specificFurther experiments were done to examine the effects
Immunity
488
Figure 6. Reversal of CD81 T Cell Tolerance
by CTLA-4 Blockade Requires CD41 T Cells
C57BL/6 mice (Thy 1.21) were used as recipi-
ents for adoptive transfer of CD81 cells from
OT-I 3 C57BL/PL mice (Thy 1.11). Some re-
cipients were depleted of CD41 T cells by
treatment with anti-CD4 antibody (500 mg/
day) on either days 21, 0, and 1 for day 10
analysis or days 8, 9, and 10 for day 22 analy-
sis (anti-CD4). OT-I/PL (Thy 1.11) CD81 T cells
(4 3 106) were transferred at day 21, and on
day 0 they were challenged by i.p. injection
of 4 3 106 E.G7 cells. All groups received
either an isotype control antibody or anti-
CTLA4 mAb at 250 mg/day on days 2, 4, and
6 for day 10 analysis or days 12, 14, and 16
for day 22 analysis. (A) OT-I cells in the drain-
ing LN and PC were determined at day 10
and 22. Groups included two mice each, and
results are shown as average and range of
values. ND, not determined. The experiment
shown is representative of two independent
experiments. (B) E.G7 tumor cell numbers
were determined from the PC of mice from
each group described in (A). Average and
range are shown for duplicate mice in each
group. ND, not determined.
CD41 T cell help generated by priming with OVA prior was substantially reduced (Figure 7B). A significant frac-
tion of the OT-I cells in the PC had high forward scatterto tumor challenge might support an effective OT-I re-
sponse in the absence of anti-CTLA-4 mAb treatment (indicative of blast transformation) and IL-2R expression
(data not shown), indicating that they were continuingor cytokine administration. This was tested by adminis-
tering OVA peptide ªISQAVHAAHAEINEAGRº in incom- to undergo activation and proliferation. Thus, the differ-
ence that results from priming is not the extent of initialplete Freund's adjuvant (IFA) prior to challenge with tu-
mor. This peptide is a CD41 T cell epitope in H-2b mice clonal expansion and pool size but rather the fact that
the OT-I do not all leave the PC and become nonrespon-(Shimonkevitz et al., 1984) and allows priming of an OVA-
specific CD41 T cell population without priming the OT-I sive at longer times, i.e., induction of tolerance is pre-
vented.cells.
Mice received OT-I cells by adoptive transfer and were
either left untreated or received IFA and PBS (IFA/PBS) Discussion
or ISQAVHAAHAEINEAGR peptide in IFA (IFA/4OVAp),
and two days later the mice were challenged by i.p. Our previous (Shrikant and Mescher, 1999) and current
results allow a detailed quantitative description of theinjection of E.G7 tumor. The number of activated OT-I
cells in the PC at day 4 was essentially the same in the OT-I CD81 T cell response to a syngeneic tumor and
the role of antigen-specific CD41 T cells in this response.controls and the primed recipients (data not shown). At
longer times, however, mice that were either unprimed Within 4 days of i.p. tumor challenge, naive OT-I migrate
into the PC, proliferate and differentiate, and controlor that received IFA/PBS had few if any OT-I cells in the
PC but significant numbers in the spleens and LN (Figure tumor burden. Thus, clonal expansion occurs at the tu-
mor site rather than in draining LN. This initial response7A). This is the expected result for early expansion of
OT-I in the PC, followed by migration away from the PC requires IL-2 (Figure 4), but CD41 T cells were not re-
quired since virtually identical levels of OT-I expansionand long-term nonresponsiveness. Consistent with this
interpretation, essentially all of the OT-I cells in the and tumor reduction where seen when CD41 T cells
were depleted by antibody treatment (Figures 1Ab andspleen and LN expressed high CD44 levels indicating
that they had responded to antigen (data not shown). 1Ad) or when the OT-I response was examined in CD42/2
recipient mice (Figure 2). Thus, this early phase of theIn contrast, even by day 35, mice primed with IFA/4OVAp
still had high numbers of OT-I cells in the PC (Figure CD81 T cell response depends upon autocrine IL-2 pro-
duction. Furthermore, this is sufficient for a maximal7A), as well as in the spleens and LN, and tumor load
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to proliferate. Thus, OT-I cells from the spleens and LN
of EG.7-bearing adoptive transfer recipients can re-
spond to antigen in vitro if they are provided with exoge-
nous IL-2 (Shrikant and Mescher, 1999). The nonrespon-
sive state of the OT-I cells in the spleen and LN after
day 5 is therefore unlikely to be a consequence of any
unique effect of tumor but rather simply normal AINR
following a response. A similar loss of responsiveness
has been observed following an initially effective CTL
response to virus (Kyburz et al., 1993).
Administration of anti-CTLA-4 mAb can result in de-
creased tumor growth and prolonged host survival in
several tumor systems (Leach et al., 1996; Kwon et al.,
1997; Yang et al., 1997; Mokyr et al., 1998). Anti-CTLA-4
mAb also had a dramatic effect on OT-I cells responding
to EG.7 tumor, causing them to undergo prolonged
expansion and remain in the PC (Figure 1A) where they
could continue to control tumor growth (Figure 1B).
These effects were dependent on CD41 T cells and were
eliminated upon anti-CD4 mAb-mediated depletion (Fig-
ure 1) or use of CD42/2 recipients (Figure 2). Thus, it
appears that CD41 T cells can respond to antigen and
provide help to sustain the CD81 T cell response but
only when CTLA-4 interactions are blocked.
Exogenous IL-2 stimulates proliferation of CD81 T
cells that have become nonresponsive following full
stimulation (Deeths et al., 1999), suggesting that theFigure 7. Priming OVA-Specific CD41 T Cells prior to OT-I Transfer
and Challenge with E.G7 Tumor Results in a Sustained OT-I Re- help provided in vivo by CD41 T cells when CTLA-4
sponse and Prolonged Control of Tumor Growth interactions are blocked might result from them produc-
Mice received by s.c. injection either 0.3 ml of PBS (OT-I/E.G7) or ing IL-2. Consistent with this, the CD41 cells isolated
0.3 ml of IFA 1 PBS in a 1:1 ratio (OT-I/E.G7 1 IFA/PBS), or 0.3 ml from EG.7-bearing, anti-CTLA4 mAb-treated mice pro-
of IFA 1 PBS (1:1) containing 50 mg CD41 OVA peptide. Two days duce large amounts of IL-2 upon in vitro stimulation with
later, the mice received 4 3 106 OT-I cells by adoptive transfer and
antigen (Figure 3B). IL-2 was necessary and sufficientwere then challenged with 3 3 106 E.G7 at day 0. The experiment
to support the sustained OT-I response at the site of theshown is representative of two independent experiments.
tumor, as demonstrated by the findings that neutralizing(A) The numbers of OT-I cells in the PC, spleen (Spl), and draining
LN (LN) were determined on day 35. Groups included two mice anti-IL-2 mAb eliminated the enhancement caused by
each, and averages and ranges are shown. anti-CTLA-4 mAb (Figure 4) and that administration of
(B) The numbers of E.G7 cells in the PC were determined at day 35. rIL-2 at the peak of the OT-I response (days 4 and 5)
Averages and ranges for two mice per group are shown.
had effects comparable to anti-CTLA-4 mAB (Figure 5B).
The same effects of IL-2 administration were seen when
the OT-I recipients were depleted of CD41 T cells (Figure
response since early (day 4) administration of rIL-2 did 5C), confirming that the IL-2 effect is on the CD81 T cells.
not increase the response (Figure 5), and elimination of CD41 T cell help can result from CD40/CD40 ligand-
CD41 T cells caused no reduction of the response, even dependent conditioning of APC by the CD41 T cells so
when CTLA-4 mAb was given (see below). that the APC can more effectively stimulate CD81 T cells
After day 4, the activated OT-I cells leave the PC and (Bennett et al., 1998; Ridge et al., 1998; Schoenberger et
appear in the draining LN, spleen, and blood (Figure 1; al., 1998). In the tumor-specific CTL response described
Shrikant and Mescher, 1999). They retain lytic effector here, however, it appears that prolongation of the OT-I
function but are no longer at the tumor site, and the response by CD41 T helper cells is most likely due to
tumor again grows progressively. The OT-I cells are tol- their production of IL-2. The IL-2 then drives further
erized at this time and exhibit ªsplit anergyº (Otten and proliferation of the CD8 T cells after they have undergone
Germain, 1991); they have lytic activity but can no longer AINR and can no longer proliferate on their own by
proliferate in response to antigen (Shrikant and Mescher, autocrine IL-2 production.
1999). In other work, we have demonstrated that CD81 The enhanced CD81 T cell responses seen in these
T cells become anergic following initial proliferation in experiments might result from blocking CTLA-4 interac-
response to a stimulus that includes both antigen and tions on either CD41 or CD81 T cells or both. CD41 T
B7 ligand (Deeths et al., 1999). This differs, therefore, cells from anti-CTLA-4 mAb-treated mice made a much
from the classical anergy described for CD41 T cell stronger in vitro response to OVA than CD41 cells from
clones that occurs when the cells are stimulated through untreated mice, demonstrating that there is an effect on
the TCR in the absence of costimulation. Even after full the CD41 T cell response. Anti-CTLA-4 mAb can prevent
stimulation, CD81 T cells enter this state of ªactivation- in vivo tolerance induction in CD41 T cells by soluble
induced nonresponsivenessº (AINR) that is character- protein or peptide antigens (Perez et al., 1997), and EG.7
ized by an inability to produce IL-2 upon restimulation; tumor cells secrete the OVA antigen. Thus, a possible
explanation for the effects of early (days 2 through 6)if provided with exogenous IL-2 the cells can continue
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administration of anti-CTLA-4 mAb is that tolerance in- response at the site of the tumor by priming with an
OVA CD41 T cell epitope supports, but does not prove,duction of the antigen-specific CD41 T cells is pre-
vented, allowing them to respond and produce IL-2 to this model.
We have argued that tolerance of CD81 T cells is beingsustain the CD81 T cells response. Anti-CTLA-4 mAb
treatment was also effective at overcoming CD81 T cell reversed in the experiments described here. Alternative
explanations could be suggested but appear less likelytolerance when administered late (days 12, 14, and 16),
and this also depended on CD41 T cells. Thus, if toler- to account for the results. While anti-CTLA4 mAb treat-
ment causes increased OT-I expansion at the site of theance is induced in CD41 T cells by soluble OVA secreted
by the tumor, this would suggest that CTLA-4 blockade tumor, it is possible that the OT-I cells do not mediate the
reduction in tumor that occurs and that instead effectorcan not only prevent tolerance induction but can also
reverse established tolerance. Arguing against this pos- function of CD41 T cells (Hung et al., 1998) is responsi-
ble. However, mice that have not received OT-I cells dosibility is the observation that anti-CTLA-4 mAb adminis-
tered late does not reverse tolerance in TCR transgenic not have reduced tumor cell numbers when treated with
anti-CTLA4 mAb (see above). Furthermore, eliminatingDO.11 CD41 T cells induced by soluble antigen, as
tested by recall proliferation and cytokine production in CD4 T cells does not significantly change the level of
tumor cell reduction that is achieved when OT-I recipientvivo (A. K., unpublished data).
We have not formally demonstrated that tolerance is mice are treated with IL-2 (Figure 5). Thus, CD4 effector
function is clearly not the sole mechanism accountinginduced in the CD41 T cells in the absence of CTLA-4
blockade. Another possibility is that CD41 T cells are for anti-CTLA4 mAb and IL-2-dependent tumor reduc-
tion and in fact makes little or no detectable contribution.ignorant due to low levels of antigen and that CTLA-4
blockade increases their sensitivity to response. Mecha- Another alternative to reversal of CD81 T cell tolerance
is the possibility that some OT-I cells remain naive afternisms involving either tolerance or ignorance could ac-
count for the enhanced in vitro responses of CD41 T the initial response and that these become activated
and expand when the mice are treated with IL-2 or anti-cells from anti-CTLA-4 mAb-treated mice, the depen-
dence on CD41 T cells for the prolonged CD81 T cell CTLA4 mAb. It is unlikely that such cells would be pres-
ent, however. When adoptive transfer recipients areresponse, and the findings that IL-2 is necessary and
sufficient for the prolonged response. We are not aware, challenged with EG.7, the OT-I cells respond in the PC
and migrate out by day 10. When a new cohort of naivehowever, of either in vitro or in vivo evidence for CTLA-4
blockade being able to increase the antigen sensitivity OT-I were then injected i.v. into the mice, these naive
cells migrated to the PC and clonally expanded, againof naive CD41 T cells and overcome ignorance of low
levels of antigen. providing transient control of tumor (Shrikant and
Mescher, 1999). Thus, the environment in the tumor-Anti-CTLA4 mAb has no effect on the CD81 T cell
response when CD41 T cells are not present. Thus, the bearing mouse does not prevent response of naive cells,
and there is therefore no reason to expect any significantprolonged OT-I response cannot simply result from
CTLA-4 blockade preventing or reversing the AINR that number of CD8 cells to be present that have not re-
sponded (and become tolerant). This is supported byfollows the initial helper-independent response. This is
consistent with the observation that anti-CTLA-4 mAb the memory phenotype of the cells present in the mice
by days 8 to 10 and by the fact that no proliferativeblockade could not prevent or reverse AINR in CD81 T
cells in vitro (Deeths et al., 1999). It is possible, however, response above background can be detected when cells
from these mice are stimulated in vitro (Shrikant andthat there is a more subtle direct effect of CTLA-4 block-
ade on CD81 T cells that is only apparent when CD41 Mescher, 1999). Finally, the interpretation that CD81 T
cell tolerance is being reversed in vivo by IL-2 (eitherT cells are also present. For example, CD41 T cells might
need to condition APCs to present to the CD81 T cells, administered directly or produced by CD41 T cells) is
completely consistent with the fact that the nonrespon-but CD81 T cells might only respond to the conditioned
APC when CTLA-4 interactions are blocked. There is siveness that is induced in vivo in the CD81 T cells by
day 10 is completely reversed in vitro upon addition ofconflicting information available regarding the role of
CTLA-4 on CD81 T cells in limiting their in vivo respon- IL-2 (Shrikant and Mescher, 1999).
There is accumulating evidence in a number of can-siveness to antigen. Chambers et al. (1998) have shown
that memory responses are enhanced in CTLA-4-defi- cers for the presence of tumor-specific CD81 T cells with
a phenotype indicating that they have been previouslycient mice but primary responses are not, while McCoy
et al. (1999) have reported that anti-CTLA-4 mAb en- activated (D'Souza et al., 1998; Jantzer and Schendel,
1998; Lee et al., 1999), yet tumor growth is not controlled.hanced a primary CD81 T cell response.
It is also possible that CTLA-4 blockade is acting on This is exactly the situation in the mice that have re-
ceived OT-I and been challenged with EG.7; previouslyboth CD41 and CD81 T cells to cause the effects de-
scribed here. However, OT-I T cells can clearly make a activated OT-I cells with a memory phenotype are pres-
ent in the blood and lymphoid organs by day 10 but areprolonged response when provided with IL-2, and CD41
T cells from anti-CTLA-4 mAb-treated mice can produce not present in significant numbers at the site of tumor,
and tumor progresses. The OT-I cells are tolerant byIL-2 in response to antigen. Thus, the simplest model
to account for the observed effects would be one in virtue of having become activation-induced nonrespon-
sive following their initial response to antigen, and effec-which CTLA-4 blockade prevents/reverses tolerance in-
duction in the OVA-specific CD41 T helper cells that are tive help is not available to sustain the response. Both
anti-CTLA-4 mAb and IL-2 administration have beenrequired to produce IL-2 in order to achieve a sustained
CD81 T cell response or reverse established CD81 T previously shown to have therapeutic effects in murine
tumor models; the use of TCR transgenic CD81 T cellscell tolerance. The ability to achieve a prolonged OT-I
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day and then challenged by i.p. injection of 3 3 106 E.G7 cells inin an adoptive transfer system has provided insights
0.5 ml PBS.into the basis for these effects. In both cases, the effects
CD41 T cell depletion was done using 0.5 mg/animal/day of anti-of limited therapeutic intervention appear to be sus-
CD4 mAb i.p. on days 21, 0, and 11, with day 0 being the day of
tained. Administration of anti-CTLA-4 mAb on days 12 challenge with tumor. CTLA-4 blockade was achieved by i.p. injec-
through 16 results in high levels of OT-I in the PC on tion of 250 mg/day/animal of anti-CTLA-4 mAb on the days indicated
in the figure legends. To block IL-2 in vivo, anti-IL-2 mAb was admin-day 22 (Figure 6A), and tumor is still being controlled
istered i.p. at 1 mg/day/animal on the indicated days. All antibodies(Figure 6B). Similarly, when low-dose rIL-2 is adminis-
used in vivo were purified from ascites fluid and quantitated by UVtered on days 4 and 5, OT-I cells are still present in high
spectrophotometry.numbers in the PC on day 10 (Figure 5Ba), and tumor
is being controlled (Figure 5Bb). This result is particularly
Analysis by Flow Cytometrystriking since the rIL-2 must be gone well before day
Mice were sacrificed on the indicated days after tumor challenge,10, suggesting that a brief period of expansion in re-
and the spleen and LN (periaortic, mesenteric, axillary, and brachial)
sponse to exogenous IL-2 may reverse the AINR state collected, homogenized, and ammonium chloride treated to remove
so that the CD81 cells can again respond autonomously. RBC's. The PC was washed twice with 25 ml of PBS each time,
This possibility is being further investigated. and the resulting peritoneal exudate lymphocytes were adherence
depleted for 90 min in complete media at 378C. The total numberThe results obtained using anti-CTLA-4 mAb raised
of cells obtained from each site was determined by counting using athe possibility that failure of the OT-I response to persist
hemocytometer. Experiments typically included two mice per group,and provide long-term tumor growth control resulted
and averages and ranges are shown. The numbers of OT-I cells
solely from the lack of T cell help to sustain the response. present in the recipients following adoptive transfer were somewhat
This was further supported by the demonstration that variable between experiments, precluding the pooling of results
priming the adoptive transfer recipients with an OVA obtained in different experiments. The fold expansion of OT-I cells
seen at the various sites, the kinetics of these changes, and theCD41 T cell peptide epitope and adjuvant prior to chal-
phenotypes of the cells at the various sites and times of responselenge with E.G7 resulted in a sustained OT-I response
were very reproducible. Results of representative experiments are(Figure 7A) and prolonged control of tumor growth (Fig-
shown.
ure 7B). This suggests that it may be essential to target Cells (1 3 106) from each site were treated with Fc Block for 30
the CD41 T helper response in attempts to develop both min on ice and then stained with anti-CD8a-cychrome and anti-Thy
therapeutic and prophylactic cancer vaccines, and the 1.2-PE or anti-Thy 1.1-PE, and a third antibody-FITC specific for
phenotypic markers. After 1 hr on ice, cells were washed twice,feasibility of this is supported by recent demonstrations
resuspended in 0.2 ml of 1% formaldehyde, and analyzed by three-of tumor-specific CD41 T cell epitopes in human cancers
color flow cytometry using the CellQuest software package (Becton(Boon et al., 1994; Topalian et al., 1996; Halder et al.,
Dickinson). OT-I cells were identified as CD81/Thy 1.21 cells in
1997; Chaux et al., 1999; Manici et al., 1999; Pieper et C57BL/PL recipients or CD81/Thy 1.11 in CD42/2 C57BL/6 recipi-
al., 1999). ents. A detailed description of the identification of the OT-I cells in
the recipients has been previously described (Shrikant and Mescher,
1999).Experimental Procedures
Phenotypic characterization of OT-I cells was done using a third
FITC-labeled mAb. CD81/Thy 1.21 or CD81/Thy 1.11 cells wereMice and Cell Lines
OT-I TCR transgenic mice (Hogquist et al., 1994), a kind gift from gated, and their numbers and phenotype determined as a percent-
age of the total population. The numbers of tumor cells were deter-Dr. Francis Carbone (Monash Medical School, Victoria, Australia),
were bred to wild-type C57BL/6 or Thy 1 congenic C57BL/PL mice, mined by gating on large granular cells that were Thy 1.21/CD82.
The total numbers of OT-I and tumor cells at each location wereand these mice heterozygous for the OT-I TCR were used as the
source of transgenic T cells in all experiments. C57BL/6 CD42/2 or determined by multiplying the percent of cells in the population by
the total number of cells recovered from each site. All experimentsC57BL/PL mice were from Jackson Laboratory (Bar Harbor, ME).
Recipient mice received OT-I T cells from Thy 1 congenic mice in included two mice per group, and the range of the duplicates is
shown.all experiments described. All animals were housed under specific
pathogen-free conditions at all times. E.G7 tumor, EL-4 thymoma
derived from C57BL/6 mouse (H-2b) and transfected with the gene
Cell Proliferation and IL-2 Assaysfor OVA (Moore et al., 1988), was maintained in vitro in complete
Spleen and LN T cells from OT-I transferred and tumor-challengedRPMI media containing 400 mg/ml of G418. Cell lines were periodi-
mice were adherence depleted and the CD41 cells purified usingcally passaged in vivo.
negative selection columns (Biotex Laboratories, Edmonton, Al-
berta, Canada). The purified populations were routinely greater than
Antibodies and Reagents
85% CD41 and less than 1% CD81. For proliferation measurements,
Anti-CD8a-cychrome, anti-Thy 1.2-PE, anti-Thy 1.1-PE , and anti-
1 3 105 CD41 T cells in complete RPMI media were stimulated with
CD25-FITC mAbs and anti-CD16/CD32 antibody (Fc Block) were
1 3 106 irradiated spleen cells from naive C57BL/6 mice pulsed for
purchased from PharMingen. Additional antibodies used included
12 hr with the indicated concentrations of OVA. On day 3, cultures
anti-CTLA-4 mAb, clone UC10-4F10 (Walunas et al., 1994), anti-
were pulsed with 1 mCi of [3H]thymidine for 6±8 hr, lysed with distilled
mouse IL-2 mAb, clone S4B6-ATCC, and anti-CD4 mAb, clone GK
water, and [3H]thymidine incorporation determined. For measuring
1.5 (Dialynas et al., 1983). OVA peptide ISQAVHAAHAEINEAGR, a
IL-2 production, 5 3 105 CD41 T cells stimulated with 1 3 106 irradi-
CD41 T cell epitope in C57BL/6 mice (Shimonkevitz et al., 1984),
ated spleen cells from naive C57BL/6 mice were pulsed for 12 hr
was synthesized by the Microchemical Facility of the University of
with 1.0 mg/ml of OVA. On day 3, aliquots of culture supernatant were
Minnesota.
collected and IL-2 measured by ELISA using commercial reagents
(PharMingen). Each sample was quantitated in triplicate, and the
Adoptive Transfer, Tumor Challenge, and In Vivo standard error of mean is shown.
Antibody Administration
LN cells (axillary, brachial, mesenteric, inguinal, cervical, periaortic,
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